Amiri Mina, Molavi Ommoleila, Sabetkam Shahnaz, Jafari Sevda, Montazersaheb Soheila
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Anatomy, Faculty of Medicine, university of Kyrenia, Kyrenia, Northern Cyprus.
Cancer Cell Int. 2023 Sep 13;23(1):200. doi: 10.1186/s12935-023-03058-7.
A growing body of evidence indicates that the anticancer effect of the immune system can be activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a result of the activation of an immunomodulatory response, is called immunogenic cell death (ICD). This regulated cell death occurs because of increased immunogenicity of cancer cells undergoing ICD. ICD plays a crucial role in stimulating immune system activity in cancer therapy. ICD can therefore be an innovative route to improve anticancer immune responses associated with releasing damage-associated molecular patterns (DAMPs). Several conventional and chemotherapeutics, as well as preclinically investigated compounds from natural sources, possess immunostimulatory properties by ICD induction. Natural compounds have gained much interest in cancer therapy owing to their low toxicity, low cost, and inhibiting cancer cells by interfering with different mechanisms, which are critical in cancer progression. Therefore, identifying natural compounds with ICD-inducing potency presents agents with promising potential in cancer immunotherapy. Naturally derived compounds are believed to act as immunoadjuvants because they elicit cancer stress responses and DAMPs. Acute exposure to DAMP molecules can activate antigen-presenting cells (APCs), such as dendritic cells (DCs), which leads to downstream events by cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs). Natural compounds as inducers of ICD may be an interesting approach to ICD induction; however, parameters that determine whether a compound can be used as an ICD inducer should be elucidated. Here, we aimed to discuss the impact of multiple ICD inducers, mainly focusing on natural agents, including plant-derived, marine molecules, and bacterial-based compounds, on the release of DAMP molecules and the activation of the corresponding signaling cascades triggering immune responses. In addition, the potential of synthetic agents for triggering ICD is also discussed.
越来越多的证据表明,免疫系统的抗癌作用可通过对垂死癌细胞的免疫原性调节来激活。由于免疫调节反应的激活而导致的癌细胞死亡被称为免疫原性细胞死亡(ICD)。这种程序性细胞死亡的发生是因为经历ICD的癌细胞免疫原性增加。ICD在癌症治疗中刺激免疫系统活性方面起着关键作用。因此,ICD可能是改善与释放损伤相关分子模式(DAMPs)相关的抗癌免疫反应的创新途径。几种传统化疗药物以及临床前研究的天然来源化合物,通过诱导ICD具有免疫刺激特性。天然化合物因其低毒性、低成本以及通过干扰对癌症进展至关重要的不同机制来抑制癌细胞,而在癌症治疗中备受关注。因此,鉴定具有诱导ICD能力的天然化合物可为癌症免疫治疗提供具有潜在前景的药物。天然衍生化合物被认为可作为免疫佐剂,因为它们能引发癌症应激反应和DAMPs。急性暴露于DAMP分子可激活抗原呈递细胞(APC),如树突状细胞(DC),进而通过细胞毒性T淋巴细胞(CTL)和自然杀伤细胞(NK)引发下游事件。天然化合物作为ICD诱导剂可能是诱导ICD的一种有趣方法;然而,应阐明决定一种化合物是否可用作ICD诱导剂的参数。在此,我们旨在讨论多种ICD诱导剂的影响,主要关注天然药物,包括植物来源、海洋分子和基于细菌的化合物,对DAMP分子释放以及触发免疫反应的相应信号级联激活的影响。此外,还讨论了合成药物触发ICD的潜力。